|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.94 USD | -0.13% |
|
-12.07% | -22.99% |
| 05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
| 05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
NeuroPace, Inc. Reaffirmed earnings guidance for the year 2024. For the period, the company expects total revenue to range between $73 million and $77 million, representing growth of 12% to 18% over 2023.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.99% | 229M | |
| +11.31% | 225B | |
| +15.50% | 197B | |
| +18.83% | 143B | |
| +30.38% | 111B | |
| +2.62% | 64.72B | |
| +18.31% | 54.44B | |
| +4.96% | 51.06B | |
| +9.95% | 45.03B | |
| +4.27% | 37.4B |
NEUROPACE, INC. 
